Renaissance Technologies (RenTech)'s AVIR Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 1.17 M shares of Atea Pharmaceuticals, Inc. (AVIR) worth $6.28 M, representing 0.01% of the portfolio. First purchased in 2021-Q3, this medium-term investment has been held for 19 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in AVIR, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2023, adding 635,682 shares. Largest reduction occurred in Q2 2022, reducing 502,000 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Atea Pharmaceuticals (AVIR) Holding Value Over Time
Track share changes against reported price movement
Quarterly Atea Pharmaceuticals (AVIR) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -22,100 | Reduce 1.86% | 1.17 M | $5.38 |
| Q4 2025 | -39,400 | Reduce 3.21% | 1.19 M | $3.57 |
| Q3 2025 | -6,200 | Reduce 0.50% | 1.23 M | $2.90 |
| Q2 2025 | -44,300 | Reduce 3.47% | 1.23 M | $3.60 |
| Q1 2025 | +61,800 | Add 5.08% | 1.28 M | $2.99 |
| Q4 2024 | +9,500 | Add 0.79% | 1.22 M | $3.35 |
| Q3 2024 | +65,600 | Add 5.75% | 1.21 M | $3.35 |
| Q2 2024 | +18,100 | Add 1.61% | 1.14 M | $3.31 |
| Q1 2024 | -372,903 | Reduce 24.92% | 1.12 M | $4.04 |
| Q4 2023 | +141,762 | Add 10.47% | 1.5 M | $3.05 |
| Q3 2023 | -8,841 | Reduce 0.65% | 1.35 M | $3.00 |
| Q2 2023 | +635,682 | Add 87.35% | 1.36 M | $0.00 |
| Q1 2023 | +107,100 | Add 17.26% | 727,700 | $0.00 |
| Q4 2022 | +23,200 | Add 3.88% | 620,600 | $0.00 |
| Q3 2022 | -65,600 | Reduce 9.89% | 597,400 | $5.69 |
| Q2 2022 | -502,000 | Reduce 43.09% | 663,000 | $7.10 |
| Q1 2022 | +544,200 | Add 87.66% | 1.16 M | $7.22 |
| Q4 2021 | +598,200 | Add 2646.90% | 620,800 | $8.94 |
| Q3 2021 | +22,600 | New Buy | 22,600 | $35.04 |
Renaissance Technologies (RenTech)'s Atea Pharmaceuticals Investment FAQs
Renaissance Technologies (RenTech) first purchased Atea Pharmaceuticals, Inc. (AVIR) in Q3 2021, acquiring 22,600 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Atea Pharmaceuticals, Inc. (AVIR) for 19 quarters since Q3 2021.
Renaissance Technologies (RenTech)'s largest addition to Atea Pharmaceuticals, Inc. (AVIR) was in Q2 2023, adding 1,363,382 shares worth $5,099.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 1,166,400 shares of Atea Pharmaceuticals, Inc. (AVIR), valued at approximately $6.28 M.
As of the Q1 2026 filing, Atea Pharmaceuticals, Inc. (AVIR) represents approximately 0.01% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Atea Pharmaceuticals, Inc. (AVIR) was 1,496,303 shares, as reported at the end of Q4 2023.